Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 7
2007 17
2008 13
2009 27
2010 26
2011 29
2012 18
2013 16
2014 20
2015 31
2016 28
2017 33
2018 24
2019 34
2020 51
2021 32
2022 28
2023 27
2024 32
2025 33
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Results by year

Filters applied: . Clear all
Page 1
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial.
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, Tanaka H, Ko R, Amano Y, Tachihara M, Suzuki T, Tanizaki J, Sugawara S, Zenke Y, Shirai Y, Hayashi T, Mori K, Takahashi K. Shukuya T, et al. Among authors: kaira k. Lancet Oncol. 2025 Mar;26(3):331-342. doi: 10.1016/S1470-2045(25)00001-4. Lancet Oncol. 2025. PMID: 40049197 Clinical Trial.
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, Movsas B, Xiao C, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha R, Onitilo AA, Chen Y, Stinchcombe TE, Wang X, Paulus R, Bradley JD. Higgins KA, et al. Among authors: kaira k. J Clin Oncol. 2026 Mar 10;44(8):630-640. doi: 10.1200/JCO-25-01569. Epub 2026 Jan 13. J Clin Oncol. 2026. PMID: 41529214 Free PMC article. Clinical Trial.
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Ishihara M, Kawamura T, Namba Y, Takeyasu Y, Hasegawa Y, Sato Y, Negi Y, Oba T, Sumi T, Hirata H, Funabashi H, Oya Y, Kikuchi H, Katsurada N, Nakatani T, Tanimura K, Nakagawa T, Takeda N, Asami T, Honjo O, Nagashima H, Yamaura T, Hata N, Kitazono M, Nishioka N, Tamiya A, Sakamori Y, Shigaki R, Kaira K, Honda R, Matsui T, Suzuki E, Ito K, Otsuka K, Takase N, Murakami Y, Matsuno K, Inoue S, Kisohara A, Kusumoto S, Aoshima H, Kakizaki Y, Kubo A, Hata A, Ishikawa N, Hamai K, Kanaji N, Misumi T, Matsutani N, Seki N. Ishihara M, et al. Among authors: kaira k. Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344010. doi: 10.1177/17588359251344010. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40535732 Free PMC article.
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Hata T, et al. Among authors: kaira k. Cancer Res Commun. 2025 Jul 1;5(7):1203-1214. doi: 10.1158/2767-9764.CRC-25-0157. Cancer Res Commun. 2025. PMID: 40637162 Free PMC article.
470 results